WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Y-mAbs Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-04-11 08:51 am Sale | 2022-03-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WELLINGTON MANAGEMENT GROUP LLP | 1,910,578 4.370% | -2,360,804 (-55.27%) | Filing |
| 2022-02-04 09:30 am Sale | 2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WELLINGTON MANAGEMENT GROUP LLP | 4,271,382 9.790% | -177,228 (-3.98%) | Filing |
| 2021-07-12 09:24 am Purchase | 2021-06-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WELLINGTON MANAGEMENT GROUP LLP | 4,448,610 10.210% | 2,008,801 (+82.33%) | Filing |
| 2021-02-04 11:48 am Sale | 2020-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | WELLINGTON MANAGEMENT GROUP LLP | 2,439,809 6.020% | -16,817 (-0.68%) | Filing |